Rx Industry Must Take Phase IV “Seriously,” Commissioner Tells PhRMA
Executive Summary
Pharmaceutical manufacturers need to step up their commitment to postmarketing surveillance and studies, FDA Commissioner McClellan told the Pharmaceutical Research & Manufacturers of America March 28 in Naples, Fla
You may also be interested in...
Phase IV Reporting Improves In Year After FDA Issues Challenge To PhRMA
The pharmaceutical industry appears to be doing a significantly better job in filing Phase IV study updates in a timely fashion, FDA's postmarketing database shows
Phase IV Reporting Improves In Year After FDA Issues Challenge To PhRMA
The pharmaceutical industry appears to be doing a significantly better job in filing Phase IV study updates in a timely fashion, FDA's postmarketing database shows
FDA Minds DTC “Reminder Ad” Increase, Seeks Better “Brief Summaries”
FDA is concerned that industry may be using "reminder ads" more frequently as a way to avoid including risk information in direct-to-consumer marketing